Zydus Cadila gets USFDA nod to market muscle spasms tablets
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Baclofen tablets in the strength of 5 mg, Zydus Cadila said in a statement. The product will be manufactured at the group's formulations manufacturing facility at Baddi, it added.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Baclofen | Biotechnology | Food and Drug Administration (FDA) | Pharmaceuticals | USA Health